Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

September 10, 2018

Study Completion Date

October 22, 2018

Conditions
PruritusPsoriasis Vulgaris
Interventions
DRUG

SNA-120

Pegcantratinib ointment

DRUG

Vehicle

Placebo ointment to mimic Pegcantratinib ointment

Trial Locations (38)

14623

Site 037, Rochester

15213

Site 031, Pittsburgh

20850

Site 032, Rockville

23502

Sienna 014, Norfolk

27104

Sienna 006, Winston-Salem

27626

Sienna 016, High Point

31217

Site 029, Macon

33122

Site 026, Doral

33162

Sienna 017, North Miami Beach

33406

Site 027, West Palm Beach

33770

Sienna 019, Largo

34471

Sienna 024, Ocala

37130

Site 035, Murfreesboro

40202

Sienna 023, Louisville

46168

Sienna 011, Plainfield

47150

Sienna 010, New Albany

48346

Site 039, Clarkston

55432

Sienna 002, Fridley

63117

Sienna 001, St Louis

70006

Site 038, Metairie

72916

Sienna 022, Fort Smith

73071

Site 041, Norman

75246

Sienna 021, Dallas

77030

Sienna 018, Houston

78660

Site 034, Pflugerville

78759

Sienna 012, Austin

80220

Sienna 015, Denver

84107

Sienna 007, Murray

85255

Site 025, Scottsdale

87106

Sienna 013, Albuquerque

90404

Sienna 020, Santa Monica

92123

Sienna 008, San Diego

92708

Site 028, Fountain Valley

94538

Sienna 009, Fremont

97223

Sienna 003, Portland

06032

Sienna 005, Farmington

06484

Site 030, Shelton

08520

Sienna 004, East Windsor

Sponsors
All Listed Sponsors
lead

Sienna Biopharmaceuticals

INDUSTRY